Clinical trials: Neurogenic Bladder Disorder
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Spinal Cord Injury, Neurogenic Bladder
The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury
The purpose of this research study is to evaluate the effects upon the bladder of electric stimulation of the leg's tibial nerve in people with acute spinal cord injury with an intervention called transcutaneous tibial nerve…
- Trial name
- NCT02573402
- Testing
- Transcutaneous Tibial Nerve Stimulation, Control
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis, Neurogenic Bladder
Vaginal Estriol in Multiple Sclerosis
Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS…
- Trial name
- NCT03774407
- Testing
- vaginal estriol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Texas Tech University Health Sciences Center
Neurogenic Urinary Bladder
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of…
- Trial name
- ALFACHIN (NCT00549939)
- Testing
- Alfuzosin
- Where
- 18 sites in United States, Bulgaria and 16 more
- Volunteers
- 172 people
- Sponsor
- Sanofi
Overactive Bladder
Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?
The purpose of this research study is to help determine if 10 injections of Botox ® 100 units is less painful than 20 injections of Botox ® 100 units based on effectiveness in reducing urge incontinence episodes.
- Trial name
- NCT04124939
- Testing
- OnabotulinumtoxinA 100 Units
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Wake Forest University Health Sciences
Spinal Cord Injury, Acute, Neurogenic Bladder
Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury
The purpose of this study is to see what effects sacral neuromodulation has on bladder function and quality of life in patients with acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute, Neurogenic Bladder, Incontinence, Urinary Tract Infections
- Trial name
- NCT03083366
- Testing
- PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Multiple Sclerosis, Lower Urinary Tract Symptoms
Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
The purpose of this research study is to evaluate higher neural changes following intra-detrusor injection of Onabotulinumtoxin-A (BTX-A) in patients with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive
- Trial name
- NCT03033355
- Testing
- Intra-detrusor injection of Onabotulinumtoxin-A
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Neurogenic Bladder, Spinal Cord Injuries
Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections
Participants will undergo daily gentamicin bladder instillations to determine if its use will reduce the rate of symptomatic urinary tract infections (UTIs) as well as the use of oral and intravenous antibiotics in adults with…
- Trial name
- NCT03931408
- Testing
- Gentamicin Sulfate, No instillation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Louisville
Neurogenic Bladder, Multiple Sclerosis
Brain Targets in Patients With Bladder Emptying Difficulties
The goal of this study is to identify brain centers specifically associated with "initiation of voiding" in patients with neurogenic bladder dysfunction.
- Conditions
- Neurogenic Bladder, Multiple Sclerosis, Voiding Dysfunction
- Trial name
- NCT03574610
- Testing
- Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
Bladder, Neurogenic
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit
- Trial name
- NCT00796614
- Testing
- tamsulosin hydrochloride
- Where
- 52 sites in United States, Belgium and 11 more
- Volunteers
- 231 people
- Sponsor
- Boehringer Ingelheim
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.
- Trial name
- NCT00575016
- Testing
- botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U)
- Where
- 6 sites in Egypt, Greece and 4 more
- Volunteers
- 74 people
- Sponsor
- Allergan
Urinary Urge Incontinence
Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Non-neurogenic urinary urge incontinence (UUI) is a common quality of life disorder that causes people to feel an "urgent" need to urinate.
- Trial name
- NCT01226706
- Testing
- Botulinum Toxins, Type A
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Saskatchewan Health Authority - Regina Area
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Spinal Cord Injury, Urinary Tract Infection
Colonizing Neurogenic Bladders With Benign Flora
The purpose of the research is to determine whether we can get harmless bacteria to live in the bladders of persons with spinal cord injury who practice intermittent bladder catheterization.
- Trial name
- NCT00371631
- Testing
- Insertion of urinary catheters coated with E. coli 83972
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- US Department of Veterans Affairs
Urinary Bladder, Neurogenic
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.
- Trial name
- NCT02501928
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Fesoterodine BIC 2 mg
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Detrusor Hyperreflexia
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
- Trial name
- NCT00224029
- Testing
- Oxybutynin transdermal system
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Watson Pharmaceuticals
Urinary Bladder, Neurogenic
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old.
- Trial name
- NCT01557244
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin
- Where
- 84 sites in United States, Belgium and 23 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients
- Trial name
- NCT00461292
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 12 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Allergan
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for…
- Trial name
- CONTENT2 (NCT02660359)
- Testing
- Botulinum toxin type A
- Where
- 82 sites in Argentina, Australia and 14 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan